Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.

Affiliation

Akenroye AT(1), Heyward J(2), Keet C(3), Alexander GC(4).
Author information:
(1)Department of Pediatric Allergy and Immunology, Johns Hopkins University, Baltimore, Md; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md. Electronic address: [Email]
(2)Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.
(3)Department of Pediatric Allergy and Immunology, Johns Hopkins University, Baltimore, Md; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.
(4)Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Md.

Abstract

Comment in J Allergy Clin Immunol Pract. 2021 Nov;9(11):3977-3978.